Search
Now showing items 1-10 of 2030
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.
(2021-03-19)
Advanced non-small-cell lung cancer (NSCLC) patients with EGFR T790M-positive tumours benefit from osimertinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Here we show that the size of the ...
The Emerging Role of Local Therapy in Metastatic Prostate Cancer.
(2020-01-20)
PURPOSE OF REVIEW:This review summarizes the prospective clinical evidence regarding local therapy in metastatic prostate cancer. RECENT FINDINGS:The phase 3 STAMPEDE trial showed that prostate radiotherapy confers a ...
Ubiquitin-mediated regulation of necroptosis
(Institute of Cancer Research (University Of London), 2020-01-31)
Regulated cell death is a fundamental cellular process that is critical for the development and survival of multicellular organisms. Cell death and inflammation are essential to restore tissue homeostasis following tissue ...
Prostate specific membrane antigen and DNA damage repair in advanced prostate cancer
(Institute of Cancer Research (University Of London), 2022-03-31)
Identification and implementation of novel therapeutic strategies for advanced prostate cancer (PCa) remains an urgent, unmet clinical need. Prostate Specific Membrane Antigen (PSMA), a PCa biomarker, is currently being ...
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
(2020-08)
Background The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma ...
WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer.
(2020-11-21)
Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer that lacks the oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2, making it difficult to target ...
Defining the role of SF3B1K700E mutations in ER+ breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
Mutations in SF3B1, a component of the RNA splicing machinery, underpin a number of aggressive cancers. Hotspot mutations in SF3B1 are present in around 3% of breast cancers, are enriched in oestrogen receptor positive ...
Functional studies of genome architectural proteins CTCF and ZNF143
(Institute of Cancer Research (University Of London), 2021-09-30)
The genome architecture and gene transcription are interdependent. The way chromatin is packed within the nucleus controls when and how genes are expressed. A lot of chromatin interacting proteins are involved to ensure ...
Improving outcomes for the lung cancer patient with impaired lung function
(Institute of Cancer Research (University Of London), 2021-03-31)
Lung function impairment is common amongst patients with lung cancers. Identifying the patients that are most likely to benefit from anti-cancers therapies, without suffering significant toxicities, is central to improving ...
Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) of the normal bone marrow in children and effects of local and systemic cancer therapies
(Institute of Cancer Research (University Of London), 2021-01-31)
Bone marrow, one of the largest organs in the body, is a highly proliferative tissue because of its dynamic function in providing the cellular elements of blood. In a paediatric population, the proportion of red marrow ...